文献速递肾小球疾病

氧化磷酸化抑制剂IM156通过调节线粒体膜电位抑制B细胞活化并有助于减轻系统性红斑狼疮

The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus.
PubMed 文献 · Kidney Int · 2022-11-01

本研究探讨双胍衍生物IM156对TLR-9激动剂CpG寡脱氧核苷酸刺激的过度活化B细胞代谢的调节作用。体外实验显示CD19+B细胞线粒体质量和膜电位高于T细胞,更易受IM156抑制氧化磷酸化;在NZB/W F1狼疮小鼠中,IM156抑制线粒体氧化磷酸化、细胞周期进展、浆母细胞分化和活化标志物水平,并显著提高总生存率、减轻肾小球肾炎和抑制B细胞活化。作者认为IM156可能成为B细胞过度活化介导的自身免疫病的治疗选择。

要点

  • CD19+B细胞线粒体质量和膜电位高于T细胞,对IM156抑制氧化磷酸化更敏感。
  • IM156在体内抑制CpG刺激的小鼠脾B细胞氧化磷酸化、细胞周期进展、浆母细胞分化和活化标志物。
  • IM156显著提高NZB/W F1狼疮小鼠总生存率、减轻肾小球肾炎并抑制B细胞活化。

核心结论

  • IM156抑制小鼠活化B细胞的线粒体膜电位,有助于减轻狼疮活动。
  • IM156可能成为B细胞过度活化介导的自身免疫病的治疗选择。

研究设计与样本

  • 体外和体内研究,使用TLR-9激动剂CpG寡脱氧核苷酸刺激的过度活化B细胞。
  • 通过RNA测序分析体内B细胞转录组表达,鉴定IM156影响的主要分子通路。
  • 在狼疮倾向NZB/W F1小鼠中评估IM156的抗炎作用。

主要发现

  • CD19+B细胞线粒体质量和线粒体膜电位高于T细胞,且对IM156介导的氧化磷酸化抑制更敏感。
  • 体内IM156抑制CpG寡脱氧核苷酸刺激的小鼠脾B细胞线粒体氧化磷酸化、细胞周期进展、浆母细胞分化和活化标志物水平。
  • IM156治疗显著提高NZB/W F1小鼠总生存率,减轻肾小球肾炎并抑制B细胞活化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current treatment strategies for autoimmune diseases may not sufficiently control aberrant metabolism in B-cells. To address this concern, we investigated a biguanide derivative, IM156, as a potential regulator for B-cell metabolism in vitro and in vivo on overactive B-cells stimulated by the pro-inflammatory receptor TLR-9 agonist CpG oligodeoxynucleotide, a mimic of viral/bacterial DNA. Using RNA sequencing, we analyzed the B-cell transcriptome expression, identifying the major molecular pathways affected by IM156 in vivo. We also evaluated the anti-inflammatory effects of IM156 in lupus-prone NZB/W F1 mice. CD19+B-cells exhibited higher mitochondrial mass and mitochondrial membrane potential compared to T-cells and were more susceptible to IM156-mediated oxidative phosphorylation inhibition. In vivo, IM156 inhibited mitochondrial oxidative phosphorylation, cell cycle progression, plasmablast differentiation, and activation marker levels in CpG oligodeoxynucleotide-stimulated mouse spleen B-cells. Interestingly, IM156 treatment significantly increased overall survival, reduced glomerulonephritis and inhibited B-cell activation in the NZB/W F1 mice. Thus, our data indicated that IM156 suppressed the mitochondrial membrane potentials of activated B-cells in mice, contributing to the mitigation of lupus activity. Hence, IM156 may represent a therapeutic alternative for autoimmune disease mediated by B-cell hyperactivity.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Shim JS, Kim EJ, Lee LE, et al. The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus. Kidney Int. 2022. PMID: 36332729. doi:10.1016/j.kint.2022.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。